PhoreMost inks multi-project drug target deal with Roche

UK-based biotech PhoreMost, which is dedicated to ‘Drugging the Undruggable’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Swiss pharma giant Roche (ROG: SIX).

Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for pre-clinical success-based milestones. Further financial terms are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche. Novel targets identified will be further validated and characterized by Roche’s R&D organization, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and hematology.